Reduced Dose of Abiraterone Acetate with Concomitant Low-dose Prednisone in the Treatment of = 85 Year-old Patients with Advanced Castrate-resistant Prostate Cancer

Roberto Petrioli; Edoardo Francini; Anna Ida Fiaschi; Letizia Laera; Salvatora Tindara Miano; Giovanni De Rubertis; Giandomenico Roviello

Reduced Dose of Abiraterone Acetate with Concomitant Low-dose Prednisone in the Treatment of = 85 Year-old Patients with Advanced Castrate-resistant Prostate Cancer

Journal article

Peer reviewed

Reduced Dose of Abiraterone Acetate with Concomitant Low-dose Prednisone in the Treatment of = 85 Year-old Patients with Advanced Castrate-resistant Prostate Cancer

Roberto Petrioli, Edoardo Francini, Anna Ida Fiaschi, Letizia Laera, Salvatora Tindara Miano, Giovanni De Rubertis and Giandomenico Roviello

Anticancer research, Vol.35(5), pp.3097-3102

05/01/2015

PMID: 25964601

View Online

Abstract

Aim: The aim of the study was to evaluate the activity and safety of reduced-dose abiraterone acetate (AA) in >= 85 year-old patients with advanced castrate-resistant prostate cancer (CRPC). Patients and Methods: Patients received 750 mg oral AA as three 250-mg tablets once daily, with concomitant oral prednisone, 5 mg daily. Results: Twenty-six patients were enrolled; median age was 88 years (range=85-93). Prostate-specific antigen (PSA) response was observed in 18 (69.2%) subjects, median time to PSA progression was 6.4 months (95% confidence interval (CI)=2.8-8.8) and median overall survival was 14.3 months (95% CI=7.2-18.3). The treatment was well-tolerated and adverse events, related to mineralocorticoid excess, were of grade 1-2 in all patients. Conclusion: Reduced dose of AA combined with a very low dose of prednisone is effective and well-tolerated in very elderly patients with advanced CRPC.

Life Sciences & Biomedicine

Oncology

Science & Technology

Details

Title: Subtitle: Reduced Dose of Abiraterone Acetate with Concomitant Low-dose Prednisone in the Treatment of = 85 Year-old Patients with Advanced Castrate-resistant Prostate Cancer
Creators: Roberto Petrioli - University of Siena
Edoardo Francini - Univ Rome, Policlin Umberto I Hosp, Med Oncol Unit, Rome, Italy
Anna Ida Fiaschi - University of Siena
Letizia Laera - University of Siena
Salvatora Tindara Miano - University of Siena
Giovanni De Rubertis - University of Siena
Giandomenico Roviello - University of Siena
Resource Type: Journal article
Publication Details: Anticancer research, Vol.35(5), pp.3097-3102
PMID: 25964601
ISSN: 0250-7005
eISSN: 1791-7530
Publisher: Int Inst Anticancer Research
Number of pages: 6
Language: English
Date published: 05/01/2015
Academic Unit: Internal Medicine
Record Identifier: 9985221242502771

Metrics

1 Record Views

7 Times Cited - Web of Science